TCM
ALXN

Tekla Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Tekla Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-18,200
Closed -$2.85M – 160
2015
Q3 		$2.85M Buy
+18,200
New +$3.32M 0.1% 129
2015
Q2 		– Sell
-77,200
Closed -$13.4M – 135
2015
Q1 		$13.4M Buy
+77,200
New +$14M 0.53% 47
2014
Q4 		– Sell
-26,800
Closed -$4.44M – 115
2014
Q3 		$4.44M Buy
+26,800
New +$4.4M 0.21% 83

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Tekla Capital Management's ALXN Position: Q3 2021 in Review

Tekla Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 64,453 shares — an estimated $11.8M sold.

Tekla Capital Management first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $121M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Tekla Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Tekla Capital Management sold 64,453 Alexion Pharmaceuticals shares in Q3 2021, an estimated $11.8M.
  • Tekla Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Tekla Capital Management's Alexion Pharmaceuticals position peaked at $121M in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.